Skip to main content

Alaunos Therapeutics, Inc.

TCRT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001107421

No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Alaunos Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of TCRT: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders27229+4
Shares108.5K30.4K125.9K+47.7K (+61.1%)
Value$349.9K$98.1K$360.5K+$108.7K (+43.2%)

2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to TCRT in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Fiduciary Trust Co15,497$44.3K0.00%
Vanguard Capital Management LLC14,063$40.2K0.00%
Citadel Advisors LLC10,519$30.1K0.00%
XTX Topco Ltd10,174$29.1K0.00%
Vanguard Global Advisers, LLC501$1.43K0.00%
Royal Bank of Canada185$1.00K0.00%

Sold out (2)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of TCRT in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Bank of America Corp89$287
Tucker Asset Management LLC1$3

Not filed for Q1 2026 yet (2)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TCRT in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc30,061$97.1K
CIBC Private Wealth Group, LLC300$969